 Keros Therapeutics, Inc. Keros KROS, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced the closing of its initial public offering of 6,900,000 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase up to 900,000 additional shares, at a public offering price of 16.00 per share, for total gross proceeds of 110.4 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the shares of common stock were sold by Keros. 